🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.

Thoughts on Healthcare Markets & Technology

Why AI Hollows Out Healthcare Services That Resell Repeatable Admin Labor and Rewards Accountable Data-Rich Operators: Ranking Five Exposed Legacy Models and Five Archetypes Built to Win

The American healthcare industry spends about $19.7B a year fighting payer denials. Roughly 54% of denied claims eventually get overturned. The industry pays close to twenty billion dollars annually to be told it was right all along. AI is now pointed directly at this…

Listen now

6 minutes ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of Contents

1. The thesis in plain English

2. Why the billing unit decides who gets hurt

3. The five legacy models with a target on their back

4. Two near misses: pharma document shops and CRO back offices

5. The five archetypes with a real shot at winning

6. Diagnostics and care management, where it is augmentation and not replacement

7. Who actually keeps the savings

8. Five things that would change the rankings

9. The base case through 2029

Abstract

- AI is not killing healthcare services. It is deleting minutes from discrete, documented, rules-heavy tasks: typing, extraction, routing, status checks, first drafts, coding suggestions, first-pass review.

- That breaks any vendor priced per FTE, per line, per page, per case or per transaction, because the buyer gets the first dollar of savings and then asks for a lower price, insources, or buys the workflow from the EHR or payer core platform.

- Most exposed, in order: labor-only transcription and synchronous scribing; commodity RCM, coding and claims follow-up BPO; routine patient access and contact centers; payer intake, prior auth and routine UM ops; generic HIT staff aug and document factories.

- Best positioned: end-to-end RCM managed services that own exceptions and price on outcomes; hybrid AI plus human documentation and access ops sold as a result; licensed-human payer ops and payment integrity with audit trails; specialist interoperability and managed AI operations; AI assurance, security, clinical validation and regulated biopharma delivery.

- Pharma document factories and CRO back offices carry very high task exposure but only moderate business exposure through 2029, because GxP sign-off, scientific judgment and physical site work stay stubbornly human.

- Diagnostics, care management and specialty pharmacy support are augmentation first. The money goes to whoever holds the integrations, the outcome data, the exception queue and the contract language.

- Five tells to watch: independently audited production evidence, contract migration away from FTE pricing, platform absorption by EHR and payer cores, policy execution on CMS-0057-F and the HIPAA Security Rule NPRM, and longitudinal safety and equity data.

Read more

But AI is not killing healthcare services broadly. It is deleting minutes from specifi…

Read more

🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.

Thoughts on Healthcare Markets & Technology

Sorting startup wedges from noise in Q3 2026 commercial payer bulletins on UHC stage 3 Tzield, Cigna glioma LITT, infusion site of care, Elevance off-campus billing and Georgia gold cards

Payer bulletins are where reimbursement actually moves. An FDA approval says a drug can be sold. A line in a medical policy says one insurer will cover it for a patient with specific lab values starting on a specific date. Q3 2026 had five changes worth knowing about…

Listen now

2 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

Q3 2026 (July 1 to Sept 30) produced the usual pile of commercial payer bulletins. Five changes from that pile get sorted here by one test, whether the change supports a new company or just hands an existing vendor a feature. Two add a clinical indication that wasn’t covered before and three change how existing care gets authorized or paid. None is a mandate, so all five are payer-policy tailwinds and nothing sturdier.

UHC commercial, effective Oct 1. Tzield for recently diagnosed stage 3 T1D, with at least one positive pancreatic islet cell autoantibody and peak C-peptide of at least 0.2 pmol/mL, max two 12-dose courses per lifetime. The bulletin does not limit this pathway to ages 8 to 17. The FDA indication remains stage 2 T1D in adults and children aged 1 year or older; UHC’s new policy language separately addresses stage 3 T1D.

Cigna policy 0528, effective Nov 15. LITT for newly diagnosed glioblastoma or other glioma, with the lesion cap moving from 30 cc of volume to 3 cm of diameter (about 14 cc).

UHC site of care, effective Oct 1. Seven products added to the list, four of them twice-a-year subQ shots.

Elevance, announced Sept 29. Physical location on hospital claims plus off-campus rates, rolling out across 2026 and 2027, ahead of a federal off-campus NPI and attestation deadline of Jan 1, 2028.

Georgia gold cards, live since July 1. Fully insured plans mostly, with Aetna, UHC and Anthem each running a different rulebook.

Verdict. Tzield ops first for a clinical-services team, Elevance location data first for a software team, and the other three are features.

Table of Contents

Why anyone should read payer bulletins

The Tzield pathway and the eight week clock

What the Tzield math looks like

LITT for new gliomas, with a geometry problem

Site of care and the seven new names on the list

Elevance wants to know where the building is

Georgia gold cards and three different rulebooks

The prior auth bot problem and other leftovers

Ranking the five and what would change the order

Why anyone should read payer bulletins

Payer policy bulletins are the least loved documents in healthcare, and that’s in a field that includes EOBs. UHC’s September commercial bulletin runs 32 pages, most of it tables where the left column says what changed and the right column reprints the entire policy in case anyone missed it. Cigna’s August update manages to cover breast reduction after GLP-1 weight loss, photopheresis, Alzheimer’s antibodies and the step therapy ladder for Xeljanz in one PDF. Nobody reads these for fun. Billing managers skim for their own specialty, and founders mostly learn what was in them when a customer calls to say the product broke. That’s a waste, bc the bulletins are where reimbursement actually moves. An FDA approval says a drug can be sold. A line in a medical policy says one payer will cover it for a kid with specific lab values starting on a specific date, and that second document is the one a business can be planned around. It also shows up with zero press coverage a few months after the first.

The quarter that ended Sept 30 had at least five changes worth a look, and they split into two bins. Two of them add a clinical indication that wasn’t covered before. The other three change how existing care gets authorized or paid. A new company might fit in the first bin. The second bin is mostly where an existing vendor ships a feature and sends a product update email. Several of the five were announced in Q3 but don’t take effect until October or November, so the window to do something about them is open right now. One caveat before the details, since this audience will ask. None of the five is a mandate. No broad final federal or state coverage requirement turned up in the quarter’s output, and not finding one in a stack of PDFs doesn’t prove there isn’t one. These are commercial payers editing their own rules, so each rule covers only that payer’s book and bends to plan documents and employer choices. It can also be edited again next quarter. A coverage policy isn’t a promise to pay either (every bulletin says so in the fine print, usually twice). The rankings further down are judgment calls from reading documents, and no customer has been asked what they’d pay for any of it.

Read more

United Healthcare added a stage 3 type 1 diabetes pathway for Tzield, effective October…

Read more

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of Contents

Nine seconds of health spending

What the notice asked for, and who was allowed to answer

The Sovereign Execution Bridge, translated out of grant-speak

Identity and authorization, or who is this thing and who said it could

Audit and provenance, or two fields and a prayer

Clinical responsibility and the liability hot potato

Five candidates for the keys

The lab award is the boring half that matters

What to build, what to watch

Abstract

ONC announced the 2026 LEAP in Health IT awardees on Oct 6: two cooperative agreements totaling approximately $1.5 million.

Area 1 (agentic AI, up to $1 million) went to MedStar Health Research Institute for an open-source middleware layer called the Sovereign Execution Bridge.

Area 3 (laboratory interoperability, up to $500,000) went to Regenstrief Institute for a toolkit to assess readiness, identify terminology and interoperability gaps, and guide remediation at small independent laboratories.

Area 2 (a community feedback layer for FHIR endpoints through Lantern, ONC’s FHIR endpoint monitoring tool, with a $500,000 ceiling) received no award; ONC said it received applications only for Areas 1 and 3.

MedStar’s design: durable long-running workflows, patient-gated Solid pods, and cryptographically verifiable AI routing with tamper-evident certificates.

The dollars are small. The funded design is the news: the patient holds the keys, while the commercial market is handing them to EHR vendors, health systems, payers and chatbot companies.

Five things an agent needs that a chatbot never did: identity, authorization, audit, provenance, clinical responsibility.

Backdrop: HTI-5 still pending, FDA’s generative AI paper, ARPA-H’s ADVOCATE, Epic’s Agent Factory, America.gov, and a summer of test agents wandering where nobody invited them.

Company shapes: execution brokers, receipts and audit, agent credentialing, clinical saga libraries, lab code remediation.

Read more

ONC’s LEAP program has made 20 awards since 2018. Its 2018 award for bulk Fast Healthcare Interoperability Resources data export became a federal certification requireme…

Read more

Thoughts on Healthcare Markets & Technology

Business plan for an AI-first, VC-backed tech-enabled services company that sells half-stars to Medicare Advantage plans: 2027 Star Ratings math, pharmacy wedge, pricing, margins and risks

The 2027 Medicare Advantage Star Ratings dropped Oct 8. The headline barely moved. Everything underneath it did. A thread on what that means for health plans and the companies that sell them stars…

Listen now

6 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of Contents

The scoreboard CMS posted on Oct 8

What a half-star is worth

Why a services company and why AI now

The wedge is pharmacy

Products two and three: HEDIS, then the surveys

Pricing a product that pays off in 2030

Unit economics

Who buys and when

The raise, the team and the first 36 months

What kills it

Exit math

Abstract

2027 Star Ratings posted Oct 8, 2026. CMS rated 508 MA-PD contracts, 188 at 4+ stars (37%), down from 44% in 2026, and about 71% of MA-PD enrollees are in 4+ star contracts.

Proposed company is an AI-first Stars operator that takes over whole measures and gets paid mostly on movement. Pharmacy first, HEDIS second, CAHPS and HOS last.

The two physical- and mental-health improvement measures rise to triple weight for the 2027 Star Ratings. The Medication Therapy Management Comprehensive Medication Review measure returns for the 2029 Star Ratings, based on measurement year 2027. Results post in October 2028 and affect 2028 quality-bonus payments.

Financing is $7M seed now, approx $28M Series A in late 2027, approx $70M Series B after the first public scoreboard. Target approx $140M revenue by 2031 at 60%+ GM.

Kill list is the curve, CMS rewrites, the courts, PBM data access, the cash lag and one bad AI phone call.

Read more

Of 508 rated contracts, only 188 hit 4 stars or better. That is 37%, down from 44% last year. Five-star contracts fell from 22 to 15. Smaller plans slipped wh…

Read more

Thoughts on Healthcare Markets & Technology

A bootstrapper’s business plan for the 2026 Transparency in Coverage final rule (CMS-9882-F): network IDs, taxonomy files, attestations and phone lines the VC-backed data shops will pass on

A 338-page federal rule just quietly reshuffled the health data startup market. Here is what actually happened with the Transparency in Coverage final rule and where the real opportunities landed…

Listen now

7 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of Contents

What got finalized and what got cut

The moat got cheaper on purpose

Compliance plumbing for the 1,508 filers

The attestation and the name in the file

The phone line is the ongoing cost

Picks and shovels for the 300 file users

The taxonomy file is a denial rulebook

Rosters, OON benchmarks and the employer graph

Calendar, cost stack and pricing

What can go wrong

Abstract

Rule: CMS-9882-F, the tri-agency Transparency in Coverage (TiC) final rule. Filed for public inspection Oct. 5, 2026, and scheduled for Federal Register publication Oct. 6, 2026; 338 Federal Register pages. The final rule is effective 60 days after official publication.

What changed: one INN file per network with a network name and ID, OON files split into 4 markets with an 11-claim floor, quarterly posting, a single format (JSON), an exec attestation, three new files (Taxonomy, Utilization, Text) and cost estimates by phone.

What got cut: the Change-log File, enrollment totals, claims volume, any retention mandate, any API, any CMS-run registry of network IDs.

The rule’s own numbers: 1,303 issuers, 205 TPAs, about 2.77M ERISA plans, about 300 file users, roughly $400M one-time cost, $80.4M a year ongoing, $174.5M a year net savings from year two.

Thesis: parsing gets cheap, so the national rate warehouse stays the VC lane. The bootstrapped lane is whatever the Departments declined to standardize, plus the chores a 40-person filer can’t staff.

Plays: compliance kit, attestation QA, phone estimate line, network ID registry, percent-of-charge dollarizer, diff feed and archive, taxonomy compiler and denial lookup, utilization rosters, OON benchmarks, employer graph.

Dates: Jan 1, 2027 plan years (phone), five months after publication (first new INN and OON files), 11 months after publication (Taxonomy and Text Files), Dec 2027 (Rx files), and the first Utilization File 21 months after publication.

Read more

The monthly in-network machine-readable file corpus has been running over 1 petabyte. The rule is expected to cut that by roughly 70%. Full-copy storage drops …

Read more

🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.

Thoughts on Healthcare Markets & Technology

Rochester General's 80-of-82 residency class, 832 voided USMLE scores, and why the foreign medical graduate fight is two separate problems (seat math and exam integrity) with separate fixes

An anonymous post claimed 80 of 82 Rochester General residents are visa holders. The Dept of Labor inspector general amplified it within 72 hours. A senator called it structural rigging. A state senator called it racist. All of that happened in one weekend…

Listen now

10 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of Contents

- The tweet, the watchdog, and 82 headshots

- Who wants these seats, per the Match

- How a hospital ends up with a class like Rochester’s

- The 832 problem

- Where the credential stack runs thin

- Visa whiplash

- Two ledgers, two sets of fixes

- The best objections

- What to watch next

Abstract

- Trigger: anonymous X account says 80 of 82 incoming Rochester General residents are on H-1B/J-1 visas. DOL inspector general amplifies it Sept 27 and demands the numbers. Unverified. Public information does not establish visa status, and Rochester Regional Health has not confirmed the claim.

- Seat math: 2026 Match produced 38,354 PGY-1 matches. IMGs took 9,682, about 25%. US MD seniors matched at 93.5%, DO seniors at 93.2%. Family medicine offered 5,491 positions and left 899 unfilled after the algorithm; SOAP placements subsequently raised its overall fill rate to 98.6%. Approx. 590 US seniors finished the cycle unplaced.

- Integrity: Jan 2024, USMLE invalidated scores for 832 examinees tied to one Nepal test center. The episode was real and narrow, and was identified through the exam program’s own analysis after tips, but the precise forensic details and litigation record should be attributed to the court filings rather than treated as independently established findings.

- Thin spots: Step 2 CS was discontinued in 2021, ECFMG’s accreditation policy became a notation rather than an eligibility gate in 2024, and more than 20 states have enacted pathways allowing some internationally trained physicians to obtain licensure without repeating a US residency.

- Visas: the $100,000 H-1B payment has been blocked in litigation, while DHS proposed a separate $103,265 fee through rulemaking. A four-year cap affecting F and J admissions was put on hold Sept. 14. The 2026 Match rate for visa-requiring IMGs was 54.4%.

- Proposal: two ledgers. Workforce side gets counting, more GME slots with strings, and stable visa rules tied to shortage-area service. Integrity side gets origin-blind exam forensics, an in-person skills check, a real accreditation gate, and supervision rules for no-residency licenses.

Read more

Here is what the 2026 Match data actually shows: US medical seniors matched at 93.5%, same as the …

Read more

🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.

Thoughts on Healthcare Markets & Technology

Alibaba's RADAR Beat 23 of 26 Radiologists on Abdominal CT, So Why Is US Imaging AI Stuck in Pilot? The Payment, FDA, Liability and Workflow Math Behind Clinical AI's Production Gap in 2026

Alibaba’s RADAR just outperformed 23 of 26 radiologists on abdominal CT across 146 findings. Mean AUC 0.913. Published in Science. Read times dropped ~30% with AI assist. So why is US imaging AI still stuck in pilot…

Listen now

12 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of Contents

Two Science papers and a billing fight, all in one fortnight

What RADAR showed once the telephone game is rewound

The 37,000-agent biotech and the drug Merck already paid for

The production scoreboard reads 67 to 4

Nobody gets paid to find more on a CT

FDA clears findings one at a time and RADAR brought 146

A second reader that leaves a paper trail

Who ends up owning the read

Abstract

RADAR, published in Science on Sept 17, 2026 by Alibaba DAMO Academy and the First Affiliated Hospital of Zhejiang University: 424,911 contrast abdominal CT exams, 146 findings, mean AUC 0.913 vs 0.776 for the next-best vision-language model, better than 23 of 26 radiologists, plus 10% sensitivity and about 30% faster reads when assisting.

Same day in Science: Stanford’s 37,000-agent Virtual Biotech. One week later: BCBSA tied an estimated $942 million of added spending to more-intensive hospital coding between 2023 and 2025, with AI-enabled tools identified as a contributor.

Scoreboard: 67% of provider revenue cycle teams run semi or fully autonomous agents vs 4% in clinical work (Bessemer and Bain, n=226). Imaging AI deployed at 90% of large systems, high success at 19% (JAMIA, n=43).

Blockers covered: 1,164 FDA radiology AI authorizations vs 2 Category 1 CPT codes for newer imaging AI; split technical and professional billing; per-finding FDA validation; a 73% vs 56% juror liability penalty when AI catches what the rad missed; integration and monitoring load.

Thesis: AI reaches production where one P&L owns both the cost and the benefit. For generalist imaging AI that owner is whoever employs radiologists at scale.

Read more

There are 1,164 FDA-authorized radiology AI devices in the US right now. There are 2 Category 1 billing codes for newer imaging AI. Two. Wi…

Read more

Thoughts on Healthcare Markets & Technology

What DOJ's new fraud division has actually proven: 760,000 canceled ACA enrollments, the 35 percent zero-claims stat, a $26M TRICARE TMS conviction and the telemedicine brace-mill sentences

Three federal health care fraud stories broke in one week in September 2026. Social media merged them into one. That merge is doing real damage to how people understand what was actually proven…

Listen now

13 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

Three health care fraud stories landed inside one week in late September 2026 and the internet merged them into one. This piece pulls them apart and checks each against the record.

DOJ’s National Fraud Enforcement Division: roughly 500 staff, five priorities, a June takedown of 455 defendants and $6.5B

Telemedicine sentences now landing for 2014 to 2020 conduct, incl. 10 yrs for an NP who wrote compliance books after her indictment

A $26M TRICARE TMS conviction where 32 percent of collections went back out as patient kickbacks

CMS’s Aug 31 cancellation of about 315K exchange policies covering 760K people, $2.2B in APTC, 569 broker notices and a freeze on new agents

The 35 percent zero-claims stat: enrollment duration alone gets to 28 percent

Confirmed improper enrollment is about 4 percent of the exchange. The claims run from 13 to 35

Who ate the money, which gaps remain, where the business is

Table of Contents

One week, three programs

What the Fraud Division is and what June showed

Telemedicine cases are running six to nine years behind

The TRICARE TMS case and the paid patient

What CMS did on August 31

The 35 percent problem

Who ate the money

The gaps still open and where the business is

Read more

DOJ’s new National Fraud Enforcement Division charged 455 defendants in June over $6.5B in alleged false claims. That sounds enormous. But nearly $3.5B traces to…

Read more

Thoughts on Healthcare Markets & Technology

Part I: The report card theory of giant companies: how every school subject and survival need gets its LLM moment, who gets paid when it does, and what the order means for healthcare through 2046

The inventor of the transistor didn’t collect most of the value it created. The inventor of the transformer didn’t either. The money went to whoever owned the scarce thing next door once the primitive got cheap…

Listen now

15 days ago

🎧 Part II Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.

Thoughts on Healthcare Markets & Technology

Part II: The report card theory of giant companies: how every school subject and survival need gets its LLM moment, who gets paid when it does, and what the order means for healthcare through 2046

The inventor of the transistor didn’t collect most of the value it created. The inventor of the transformer didn’t either. The money went to whoever owned the scarce thing next door once the primitive got cheap…

Listen now

15 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

The p…

Read more

This is the report card theory: the biggest companies get built when a basic building block of human life (a school subject or a survival need) …

Read more

This is the report card theory: the biggest companies get built when a basic building block of human life (a school subject or a survival need) becomes something machines can do for near zero cost.

Language went first. Arithmetic went decades earlier. Biology’s reading layer (genome sequencing) is basically done. GLP-1s cracked appetite. Shelter failed because the constraint was zoning, not physics.

Four tests sort the order: does the corpus exist, can the machine grade its own work, where does the margin migrate when cost collapses, and who controls the permission layer. Healthcare fails the permission test hardest of all.

Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more.

Thoughts on Healthcare Markets & Technology

The VC-Backed Health Tech Company the Industry Needs Right Now: A Neutral Clearing Utility for Prior Auth, Claims, and Disputes, and the Business Plan to Build the Visa of Healthcare

In 1968, the NYSE closed Wednesdays because back offices couldn’t move paper fast enough. The fix was a neutral clearing utility that nobody thinks about today. Healthcare has the same problem. It has never built the fix…

Listen now

16 days ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

• The pitch: a neutral, venture-built clearing utility that sits between payers and providers for prior authorization, clinical evidence, claims status, and disputes, with published machine-readable rules, deterministic adjudication, and a public scoreboard. Working name Switch.

• Why the market is open: the largest rails are owned by the largest payer and went dark for weeks in 2024, the second largest are owned by a consortium of plans, the third are being built by an EHR vendor for its own customers, and everyone else sells shovels for the denial war.

• Why now: CMS-0057-F prior-auth process requirements generally took effect January 1, 2026, while the API requirements generally take effect January 1, 2027, for Medicare Advantage, Medicaid and CHIP programs and managed care plans, and Qualified Health Plans on federally facilitated exchanges; the AHIP pledge extends similar goals to participating commercial plans, WISeR brings algorithmic prior auth to traditional Medicare, and LLMs made chart-to-evidence extraction inexpensive, which moved the bottleneck from reading to trust.

• TAM: five trillion of spend, about a trillion of admin, roughly $265 billion of administrative complexity waste, on the order of $60 billion in transaction handling, and a rails layer billing $4 to $6 billion today. Capturable software revenue of $15 to $25 billion a year, funded by the $265 billion both sides currently burn fighting each other.

• Build: registry (rules, directory, eligibility) first, switch (transactions) second, clearing (netting, settlement, disputes, scoreboard) third. LLMs at the edges, determinism in the core.

• Money: $300 to $400 million over five years, both-sides per-transaction pricing on a published schedule, neutrality baked into a public benefit charter with a poison pill against payer or EHR ownership, and a Visa 2008 style listing instead of a sale to a strategic.

Table of Contents

1. Wall Street closed on Wednesdays once, and healthcare never reopened

2. The company: a neutral clearing utility for the payer-provider transaction

3. Why the incumbents can’t build it, including the ones who could

4. Why now: 0057-F, the Change outage, and the agent arms race

5. Sizing it: a $265 billion friction pool with a $20 billion software business underneath

6. The product in three layers: registry, switch, clearing

7. LLMs at the edges, determinism in the core

8. Cold start: getting both sides on the rails without being owned by either

9. Business model, capital plan, and the Visa 2008 exit

10. What kills it, and the ask

Read more